<DOC>
	<DOCNO>NCT00433433</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Diagnostic procedure , fludeoxyglucose F 18 positron emission tomography ( FDG-PET scan ) , may help doctor predict patient 's response treatment help plan best treatment . It yet know whether FDG-PET scan-guided therapy effective standard therapy treat Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study FDG-PET scan-guided therapy see well work compare standard therapy treat patient previously untreated stage I stage II Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 PET Scan-Guided Therapy Standard Therapy Treating Patients With Previously Untreated Stage I Stage II Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate whether chemotherapy alone effective , less toxic , combined modality treatment , term progression-free survival ( PFS ) , patient favorable unfavorable supradiaphragmatic stage I II Hodgkin 's lymphoma fludeoxglucose F 18 positron emission tomography ( FDG-PET ) scan negative two course doxorubicin hydrochloride , bleomycin , vinblastine , dacarbazine ( ABVD ) . Secondary - Evaluate whether early change chemotherapy ABVD escalate cyclophosphamide , doxorubicin hydrochloride , vincristine , bleomycin , etoposide , procarbazine hydrochloride , prednisone ( escalated BEACOPP ) improve PFS patient FDG-PET scan positive two course ABVD . - Confirm early response FDG-PET scan predictive outcome patient randomized standard treatment arm . OUTLINE : This multicenter , randomize study . Patients stratify accord disease prognostic profile ( favorable v unfavorable ) , participate center , Ann Arbor clinical stage ( I vs II ) , availability baseline fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) scan ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I ( standard [ close accrual 6/24/2011 ] ) : Patients receive ABVD chemotherapy comprise doxorubicin hydrochloride IV , bleomycin IV intramuscularly ( IM ) , vinblastine IV , dacarbazine IV day 1 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients favorable prognostic profile receive 3 course ABVD . Patients unfavorable prognostic profile receive 4 course ABVD . Patients undergo FDG-PET scan completion 2 course ABVD . Beginning 3-4 week completion ABVD , patient undergo involved-node radiotherapy ( INRT ) 5 day week 4-6 week . - Arm II ( experimental ) : Patients receive ABVD arm I 2 course undergo FDG-PET scan . Further treatment adapt accord FDG-PET scan result . - FDG-PET negative : Patients favorable prognostic profile receive 1 additional course ABVD . Patients unfavorable prognostic profile receive 2 additional course ABVD . Patients favorable unfavorable prognostic profile randomize August 9th 2010 FDG-PET negative two course ABVD receive standard combine modality treatment consist ABVD INRT arm I . - FDG-PET positive : Patients receive ABVD arm I 2 course intensification escalate BEACOPP chemotherapy comprise cyclophosphamide IV doxorubicin hydrochloride IV day 1 , vincristine IV bleomycin IV IM day 8 , etoposide IV day 1-3 , oral procarbazine hydrochloride day 1-7 , oral prednisone day 1-14 , filgrastim ( G-CSF ) subcutaneously begin day 9 continue blood count recover . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Beginning 3-4 week completion ABVD BEACOPP , patient undergo INRT 5 day week 4-6 week . After completion study treatment , patient follow periodically least 10 year . PROJECTED ACCRUAL : A total 1,797 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma No nodular lymphocytepredominant subtype ( nodular paragranuloma ) Supradiaphragmatic Ann Arbor clinical stage I II disease Must meet criterion 1 follow prognostic subset : Unfavorable subset , define meet 1 follow criterion : Clinical stage II disease ≥ 4 nodal area involve Mediastinum hilus consider 1 nodal area Age ≥ 50 year Erythrocyte sedimentation rate ( ESR ) ≥ 50 mm/hr B symptom ESR ≥ 30 mm/hr B symptom Mediastinum/thoracic ( MT ) ratio ≥ 0.35 Favorable subset , define meeting follow criterion : Clinical stage I disease OR stage II disease ≤ 3 involved area Age &lt; 50 year ESR &lt; 50 mm/hr ( B symptom ) OR ESR &lt; 30 mm/hr ( B symptom present ) MT ratio &lt; 0.35 Previously untreated disease Planning undergo fludeoxyglucose F 18 positron emission tomography first 2 course study chemotherapy PATIENT CHARACTERISTICS : WHO performance status 03 Bilirubin ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe cardiac , pulmonary , neurologic , psychiatric , metabolic disease No unstable diabetes mellitus No malignancy within past 5 year except basal cell skin cancer adequately treat carcinoma situ cervix No known HIV infection No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
</DOC>